L.Pharma AB
ABBankruptOrg 5591238265Business and other management consultancy activities· NACE 7020Est. 2017 · 9 years old0 employees
Loading company…
Overview
L.Pharma AB is a Swedish AB, operating in the Business and other management consultancy activities sector. Incorporated in 2017, the company has 0 employees and reported revenue of SEK 13.1m in its latest annual filing.
Revenue 2022
13.1M SEK
+8% vs 2021
EBITDA margin
3.9 %
−47% vs 2021
Net profit 2022
0.3M SEK
-57% vs 2021
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
18.2 %
Very weakAmong the 20% lowest rated companies in the industry
20182022
Liquidity ratioCurrent assets ÷ Short-term debt
1.5×
WeakAmong the 30% lowest rated companies in the industry
20182022
Return on assets (ROA)Net profit ÷ Total assets × 100
4.1 %
AverageAround the average of companies in the same industry
20182022
EBITDA — year on year
SEK thousandsKey figures
Annual report 2022| Revenue | 13.1M SEK | +8% |
| EBITDA | 0.5M SEK | -47% |
| Net profit | 0.3M SEK | -57% |
| Total assets | 7.5M SEK | +65% |
| Equity | 1.4M SEK | +77% |
| Employees | 0 | — |
Company information
Legal name
L.Pharma AB
Org number
5591238265
Legal form
Aktiebolag
NACE code
Founded
4 September 2017 · 9 years
Share capital
SEK 50,000
Employees
0 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall driva konsultverksamhet och service mot GxP- klassad och medicinsk utrustning.
(no translation available)
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2022), L.Pharma AB reported revenue of SEK 13.1m, an increase of 8% on the year before. The figures on this page draw on 5 annual filings covering 2018 to 2022. The bottom line showed a net profit of SEK 303.7k, and the EBITDA margin stood at 3.9%.
At the end of 2022, equity financed 18.2% of the balance sheet, and current assets covered short-term debt 1.5 times.
Financials
Revenue
SEK millionsEBITDA
SEK thousandsIncome statement
SEK thousands| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 13,134 | 12,127 | 6,445 | 6,266 | 4,149 |
| Staff expenses | -7,552 | — | — | — | — |
| EBITDA | 518 | 982 | -3,612 | -3,809 | 329 |
| Depreciation & amort. | -63 | -33 | -24 | -17 | -6 |
| EBIT | 455 | 949 | -3,636 | -3,826 | 323 |
| Net financials | -151 | -241 | -504 | -93 | -8 |
| Profit before tax | 304 | 709 | -4,140 | -3,819 | 216 |
| Tax | — | -0 | -0 | -0 | -69 |
| Net profit | 304 | 709 | -4,140 | -3,819 | 147 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Total assets | 7,453 | 4,529 | 4,888 | 4,708 | 1,188 |
| Equity | 1,359 | 766 | 51 | -376 | 265 |
| Long-term debt | 1,156 | 350 | 953 | 899 | 25 |
| Short-term debt | 4,937 | 3,413 | 3,884 | 4,185 | 798 |
| Total debt | 6,093 | 3,763 | 4,837 | 5,084 | 823 |
Financial ratios
5-year trendEBITDA margin
3.9 %
20182022
Equity ratio
18.2 %
Very weakAmong the 20% lowest rated companies in the industry
20182022
Return on equity
22.3 %
StrongAmong the 40% highest rated companies in the industry
20182022
Net profit margin
2.3 %
WeakAmong the 40% lowest rated companies in the industry
20182022
Asset turnover
1.76×
Very strongAmong the 20% highest rated companies in the industry
20182022
Debt / equity
4.48×
Very weakAmong the 10% lowest rated companies in the industry
20182022
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 30% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginWeak
Among the 40% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginWeak
Among the 40% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Strong
Among the 40% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 40% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioWeak
Among the 40% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery weak
Among the 20% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 20% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery weak
Among the 20% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 20% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 40% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtAverage
Around the average of companies in the same industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 20% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverVery strong
Among the 20% highest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverStrong
Among the 40% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalStrong
Among the 30% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LT Chief Executive Officer | Chief Executive Officer | 2020 |
TP Chief Executive Officer | Chief Executive Officer | 2020 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
LT Board of Directors | Board of Directors | 2020 |
SE Board of Directors | Board of Directors | 2022 |
NO Board of Directors | Board of Directors | 2020 |
AM Chairman | Chairman | 2020 |
TP Chairman | Chairman | 2020 |
Former (1)
AV Deputy Board Member | Deputy Board Member | 2020 – 2020 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 75% | 75% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Sonima Group AB
L.Pharma AB Board network connections
Board members of L.Pharma AB also hold positions in 244 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tommy Per Erik Nilsson | Chief Executive Officer | 229 companiesMany roles |
| Nils Olof Karlsson | Board of Directors | 5 companies |
| Sofie Eva Terese Wirandi | Board of Directors | 4 companies |
| Anders Mattias Liss | Chairman | 4 companies |
| Leif Tore Ekberg | Chief Executive Officer | 2 companies |
Frequently asked questions
What is the Org number of L.Pharma AB?
L.Pharma AB is registered with Bolagsverket / SCB under Org 5591238265.
What is the revenue of L.Pharma AB?
L.Pharma AB reported revenue of SEK 13.1m in 2022.
Who is the CEO of L.Pharma AB?
Leif Tore Ekberg is the CEO of L.Pharma AB, in role since 2020.
Who is the chairman of L.Pharma AB?
Anders Mattias Liss chairs the board of L.Pharma AB, in role since 2020.